NCT00593606View on ClinicalTrials.gov

Safety and Tolerability Trial of Switching From Ropinirole to Rotigotine

PHASE3CompletedINTERVENTIONAL

Enrollment

124

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions

Parkinson's Disease

Interventions

DRUG

Rotigotine

Strength: 2,4,6,and 8mg/24h, form: transdermal application, once daily application

Sponsors

Lead Sponsor

All Listed Sponsors

lead

UCB Pharma

INDUSTRY